



1150 First Avenue, Suite 1050, King of Prussia, PA 19406
Office: (610) 265-7710 Fax: (610) 265-7706 Contact: info@prismpharma.com
www.prismpharma.com

Board of Directors

James L. Currie, Chairman of the Board
Managing Partner, Essex Woodlands Health Ventures

Petri Vainio, MD, PhD
Managing Director, Essex Woodlands Health Ventures

Walter Flamenbaum, MD
Founding Partner, Paul Capital

Jean-Pierre Naegeli
Partner, Paul Capital

Warren D. Cooper, MB, BS, BSc, MFPM
President and CEO

Investors

Essex Woodlands Health Ventures Fund VI
Paul Royalty Fund Holdings II

Executive Officers

Warren D. Cooper, MB, BS, BSc, MFPM, President and CEO

Daniel J. Cushing, PhD, FCP, Vice President and CSO

Kathleen P. DeLawrence, Vice President and COO

Stanley J. Musial, CPA, MBA, Vice President and CFO

Employees: 10

Law Firm: Morgan, Lewis & Bockius LLP

Auditor: Ernst & Young LLP

Bank: Silicon Valley Bank

Funding History

Round 1: \$5.0 million

Round 2: \$68.0 million

Business Description and Strategy

Prism Pharmaceuticals, Inc., founded in 2004, is a US-based, acute care specialty pharmaceutical company developing and commercializing branded cardiovascular injectable products. The company is led by Dr. Warren Cooper, a former drug development and general management executive at Merck Research Laboratories, AstraMerck, and AstraZeneca.

Prism is developing novel, differentiated pharmaceuticals to address unmet medical needs with a specific focus on medication safety in the hospital environment. Prism is preparing to launch its first product, NEXTERONE[®] (amiodarone HCl) Injection.

Products

NEXTERONE (amiodarone HCl) Injection (formerly PM101)

NEXTERONE is a novel, patent-protected, cosolvent-free form of injectable amiodarone, a leading antiarrhythmic agent, for use in both acute and emergency settings. Prism Pharmaceuticals submitted a New Drug Application (NDA) for NEXTERONE in February 2008 which was approved by the FDA in December 2008, ahead of the PDUFA date. The NEXTERONE label describes the product as not containing polysorbate 80 and benzyl alcohol and omits many of the practical solvent-based limitations that are included in the labeling of all other marketed Amiodarone IV products.

Because NEXTERONE does not contain cosolvents (polysorbate 80 and benzyl alcohol), and unlike Amiodarone IV, it can be formulated in ready-to-use premixed bags and will also be available in a pre-filled syringe. NEXTERONE is being manufactured through relationships with Baxter Healthcare Corporation, HollisterStier Laboratories, LLC, and CyDex Pharmaceuticals, Inc. Prism intends to commercialize NEXTERONE in the US market and partner the global rights to the product.

PM103

PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX[®] (clopidogrel bisulfate), an orally available anti-platelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyDex Pharmaceuticals, Inc. as an alternative dosage form to oral PLAVIX for use in the acute care setting.

NEXTERONE[®] is a trademark of Prism Pharmaceuticals, Inc.
Cordarone[®] and PLAVIX[®] are registered trademarks of sanofi-aventis.
© 2008 Prism Pharmaceuticals, Inc. All rights reserved.